Bank of America’s Biohaven Pharmaceutical Holding Company Ltd. BHVN Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2022
Q4
Sell
-25,000
Closed -$3.78M 8823
2022
Q3
$3.78M Sell
25,000
-21,600
-46% -$3.2M ﹤0.01% 3627
2022
Q2
$6.79M Buy
+46,600
New +$5.95M ﹤0.01% 3070
2020
Q1
Sell
-20,000
Closed -$1.09M 7636
2019
Q4
$1.09M Sell
20,000
-30,000
-60% -$1.49M ﹤0.01% 4444
2019
Q3
$2.09M Buy
50,000
+38,700
+342% +$1.64M ﹤0.01% 4016
2019
Q2
$495K Buy
+11,300
New +$637K ﹤0.01% 5070

Other funds holding BHVN

Bank of America's BHVN Position: Q4 2022 in Review

Bank of America sold out of Biohaven Pharmaceutical Holding Company Ltd. (BHVN) in Q4 2022, closing a stake of 427,832 shares — an estimated $64.7M sold.

Bank of America first reported a position in BHVN in Q2 2017 and held it in 22 quarters. The position peaked at $64.7M in Q3 2022. 7 funds tracked by Wall St. Rank hold BHVN as of Q4 2022.

  • Bank of America reported no remaining Biohaven Pharmaceutical Holding Company Ltd. position as of Q4 2022 after selling out during the quarter.
  • Bank of America sold 427,832 Biohaven Pharmaceutical Holding Company Ltd. shares in Q4 2022, an estimated $64.7M.
  • Bank of America first reported a position in Biohaven Pharmaceutical Holding Company Ltd. in Q2 2017 and held it in 22 quarters.
  • Bank of America's Biohaven Pharmaceutical Holding Company Ltd. position peaked at $64.7M in Q3 2022.
  • 7 funds tracked by Wall St. Rank held Biohaven Pharmaceutical Holding Company Ltd. as of Q4 2022.

Based on Bank of America's 13F filing for Q4 2022, filed 10 Feb 2023.